Exchange: NASDAQ·Updated 07:21 PM EDT

IVVD News

News
all
press releases
Invivyd Names Chairman Marc Elia CEO, Adds New Directors
(RTTNews) - Invivyd, Inc. (IVVD), the U.S. biotechnology company focused on antibody therapies for viral disease, Tuesday announced the appointment of Marc Elia as Chief Executive Officer and he will continue to serve as Chairman of the Board...
Nasdaq News: Markets
More News
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of +6.67% and -13.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
RenovoRx (RNXT) delivered earnings and revenue surprises of +37.50% and +25.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
SkinHealth Systems Inc. (SKIN) Reports Q2 Loss, Lags Revenue Estimates
SkinHealth Systems Inc. (SKIN) delivered earnings and revenue surprises of +50.00% and -1.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval
PEMGARDA’s emergency status will end on June 29, 2027, unless the company secures full FDA approval in the meantime.
Stocktwits
IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%
Invivyd posted a first-quarter revenue of $13.7 million, sharply below Wall Street’s estimates of around $18 million, according to Fiscal.ai data.
Stocktwits
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -62.50% and -25.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -50.00% and +3.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Invivyd (IVVD) Expected to Announce Quarterly Earnings on Thursday
Invivyd (NASDAQ:IVVD) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat

Advertisement|Remove ads.